Completed

Mitoxantrone and Etoposide for HIV Associated Lymphomas

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Mitoxantrone hydrochloride

+ Etoposide

Drug
Who is being recruted

Blood-Borne Infections+24

+ Urogenital Diseases

+ Genital Diseases

Over 18 Years
+12 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
See protocol details

Summary

Principal SponsorLederle Laboratories
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This study focuses on understanding the effectiveness and safety of a treatment combination for HIV-associated lymphomas, specifically large cell and immunoblastic types. Lymphomas are a type of cancer that affects the immune system. The study uses two drugs, Mitoxantrone Hydrochloride (also known as Novantrone) and Etoposide. The goal is to find a treatment that works well for people living with HIV who have these specific types of lymphomas, as they can be challenging to manage. This research could potentially lead to improved care for these patients.

NCT00002003
Principal SponsorLederle Laboratories
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCommunicable DiseasesHemic and Lymphatic DiseasesImmunologic Deficiency SyndromesImmune System DiseasesImmunoproliferative DisordersInfectionsLymphatic DiseasesLymphomaLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic TypeRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralHistiocytosisHistiocytic Disorders, MalignantLentivirus InfectionsAcquired Immunodeficiency SyndromeLymphoma, Non-HodgkinHIV InfectionsDendritic Cell Sarcoma, Interdigitating

Criteria

4 inclusion criteria required to participate
Diagnosis by pathological examination of large cell or immunoblastic lymphoma within measurable or evaluable disease.
Positive HIV antibody, positive HIV culture or antigen capture, or prior diagnosis of AIDS by the CDC criteria.
Signed written informed consent.
Pneumocystis carinii pneumonia (PCP) prophylaxis during the course of the study.
8 exclusion criteria prevent from participating
Zidovudine within 2 weeks of study entry.
Stage IE Central Nervous System lymphomas.
Conditions that preclude obtaining an informed consent.
Acute intercurrent opportunistic infection, such as Pneumocystis carinii pneumonia (PCP) diagnosed within 3 weeks.
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 3 locations

UMDNJ - New Jersy Med School

Newark, United StatesOpen UMDNJ - New Jersy Med School in Google Maps

New York Univ Med Ctr

New York, United States

Saint Luke's - Roosevelt Hosp Ctr

New York, United States
Completed3 Study Centers